Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery
|ClinicalTrials.gov Identifier: NCT02058303|
Recruitment Status : Terminated (PI leaving instutition)
First Posted : February 10, 2014
Last Update Posted : April 5, 2017
|Condition or disease||Intervention/treatment||Phase|
|Hand Injuries Wrist Injuries Finger Injuries||Drug: Exparel Forearm block Drug: Bupivacaine supraclavicular block||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Exparel (Bupivacaine Liposome Injectable Suspension) for Distal Upper Extremity Blocks in Orthopedic Surgery|
|Study Start Date :||February 2014|
|Primary Completion Date :||March 2016|
|Study Completion Date :||March 2016|
Experimental: Exparel forearm block
Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
Drug: Exparel Forearm block
20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
Other Name: bupivacaine liposome injectable suspension
Active Comparator: Bupivacaine supraclavicular block
Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
Drug: Bupivacaine supraclavicular block
20-30mL 0.5% bupivacaine
- Onset of Sensorimotor block [ Time Frame: 30 minutes ]A blinded study staff member will evaluate the subject after the block is performed. Subjects will be asked to move their hand and will be asked if they can feel a sharp sensation on specific areas of their hand. Once no movement and no feeling is detected, the block is considered successful and the time will be noted.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02058303
|United States, Louisiana|
|Ochsner Clinic Foundation|
|New Orleans, Louisiana, United States, 70121|
|Principal Investigator:||Jose Soberon, MD||Ochsner Health System|